Dandekar Atul 4

What Happened
Atul Dandekar, Chief Strategy & Business Officer of Maze Therapeutics (MAZE), exercised 7,500 stock options (cost $10.42/share, total $78,150) on May 29, 2026 and sold 7,500 shares in the open market the same day for a weighted average price of $26.34/share (gross proceeds ~$197,554). The transactions were reported on a Form 4 filed June 2, 2026. The exercise + immediate sale resulted in approximately $119,404 in proceeds before taxes and fees. The filing also reports a related derivative conversion/disposition of 7,500 shares at $0.00.

Key Details

• Transaction date: May 29, 2026; Form 4 filed June 2, 2026.
• Exercise: 7,500 shares at $10.42 each (total $78,150).
• Sale: 7,500 shares on open market at weighted avg $26.34 (gross ~$197,554); sale prices ranged $26.03–$26.64.
• Net proceeds (gross sale minus exercise cost): ≈ $119,404 before taxes/fees.
• Shares owned after transaction: not disclosed in the filing.
• Footnotes: sale was executed under a Rule 10b5‑1 trading plan adopted Sept 29, 2025; the option was fully vested as of March 17, 2025.
• No late‑filing flag is indicated in the report.

Context
This sequence—exercising vested options then immediately selling the same shares—is commonly a cashless exercise (realizing value from options rather than an open‑market purchase). The 10b5‑1 plan means the sales were executed under a pre‑arranged plan, which is typical for scheduled insider selling. The reported $0.00 derivative disposition likely reflects a conversion/settlement entry related to the option exercise; the filing’s footnotes and lines provide the full technical detail.